355 related articles for article (PubMed ID: 21826075)
1. The pharmacogenetics of antiplatelet agents: towards personalized therapy?
Ahmad T; Voora D; Becker RC
Nat Rev Cardiol; 2011 Aug; 8(10):560-71. PubMed ID: 21826075
[TBL] [Abstract][Full Text] [Related]
2. Use of genetic data to guide therapy in arterial disease.
Ross S; Nejat S; Paré G
J Thromb Haemost; 2015 Jun; 13 Suppl 1():S281-9. PubMed ID: 26149037
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of clopidogrel.
O'Connor SA; Hulot JS; Silvain J; Cayla G; Montalescot G; Collet JP
Curr Pharm Des; 2012; 18(33):5309-27. PubMed ID: 22724417
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics of clopidogrel: evidence and perspectives.
Yin T; Miyata T
Thromb Res; 2011 Oct; 128(4):307-16. PubMed ID: 21592545
[TBL] [Abstract][Full Text] [Related]
5. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of the antiplatelet effect of aspirin.
Würtz M; Kristensen SD; Hvas AM; Grove EL
Curr Pharm Des; 2012; 18(33):5294-308. PubMed ID: 22724416
[TBL] [Abstract][Full Text] [Related]
7. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance.
Würtz M; Grove EL
Curr Pharm Des; 2012; 18(33):5344-61. PubMed ID: 22724409
[TBL] [Abstract][Full Text] [Related]
8. Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms.
Shanker J; Gasparyan AY; Kitas GD; Kakkar VV
Curr Vasc Pharmacol; 2011 Jul; 9(4):479-89. PubMed ID: 21314637
[TBL] [Abstract][Full Text] [Related]
9. The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.
Yang Y; Lewis JP; Hulot JS; Scott SA
Expert Opin Drug Metab Toxicol; 2015; 11(10):1599-617. PubMed ID: 26173871
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
Máchal J; Hlinomaz O
Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
[TBL] [Abstract][Full Text] [Related]
11. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
[TBL] [Abstract][Full Text] [Related]
12. Clopidogrel Pharmacogenetics.
Pereira NL; Rihal CS; So DYF; Rosenberg Y; Lennon RJ; Mathew V; Goodman SG; Weinshilboum RM; Wang L; Baudhuin LM; Lerman A; Hasan A; Iturriaga E; Fu YP; Geller N; Bailey K; Farkouh ME
Circ Cardiovasc Interv; 2019 Apr; 12(4):e007811. PubMed ID: 30998396
[TBL] [Abstract][Full Text] [Related]
13. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of genetically determined platelet reactivity.
Laine M; Arméro S; Peyrol M; Sbragia P; Thuny F; Paganelli F; Bonello L
J Cardiovasc Transl Res; 2013 Jun; 6(3):398-403. PubMed ID: 23149816
[TBL] [Abstract][Full Text] [Related]
15. Advances in the Pharmacogenomics of Antiplatelet Therapy.
Akhtar T; Bandyopadhyay D; Ghosh RK; Aronow WS; Lavie CJ; Yadav N
Am J Ther; 2020; 27(5):e477-e484. PubMed ID: 31498157
[TBL] [Abstract][Full Text] [Related]
16. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of clopidogrel.
Sarafoff N; Byrne RA; Sibbing D
Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
[TBL] [Abstract][Full Text] [Related]
19. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
Klein MD; Williams AK; Lee CR; Stouffer GA
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018
[TBL] [Abstract][Full Text] [Related]
20. Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study.
Rosafio F; Lelli N; Mimmi S; Vandelli L; Bigliardi G; Dell'Acqua ML; Picchetto L; Pentore R; Ferraro D; Trenti T; Nichelli P; Zini A
J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):1864-1873. PubMed ID: 28576652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
